CSL stock cut to Neutral as Evans and Partners lowers target
Published on 11/18/2026 at 09:22 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSAnalyst view and next date
- Evans and Partners moved its CSL recommendation to Neutral on November 16.
- The company's next earnings release is listed for February 10, 2027.
On November 16, Evans and Partners cut its recommendation on CSL to Neutral and lowered its price target to AUD 197.24, according to a MarketScreener report citing MT Newswires. The report was published on November 16 at 8:18 p.m. Eastern time.
The move places a more cautious analyst view alongside CSL's planned management transition and its recovery agenda. MarketScreener identifies CSL's main businesses as CSL Behring, CSL Seqirus and CSL Vifor, covering plasma products, vaccines, iron deficiency and nephrology therapies.
Next results remain ahead
MarketScreener lists CSL's next earnings release for February 10, 2027, identified as the company's second-quarter fiscal 2027 release. That date is the next scheduled reporting point shown with the analyst update.
CSL stock traded at 121.11 euros on Lang & Schwarz at 09:18 CET on Wednesday, November 18.
CSL Limited stock facts
- Company: CSL Limited
- ISIN: AU000000CSL8
- Lang & Schwarz quote: 121.11 euros at 09:18 CET on November 18, 2026
- Analyst action: Evans and Partners moved the recommendation to Neutral
- Price target: AUD 197.24
The Euro Stoxx 50 provides a broader regional equity-market context for investors.
